home > products & services > publications library

Publications library

view all

Product sheets

cloe screen

In vitro metabolism

cytochrome P450 inhibition

cytochrome P450 time dependent inhibition

cytochrome P450 reaction phenotyping

microsomal stability

S9 stability

hepatocyte stability

plasma stability

microsomal binding

In vitro permeability

PAMPA

Caco-2 permeability

MDCK (wild type) permeability

MDR1-MDCK permeability

Physicochemical properties

turbidimetric solubility

thermodynamic solubility

CHI

log D

chemical stability

Protein binding

plasma protein binding

Toxicity

hERG channel inhibition (IC50 determination)

cloe select

In vitro metabolism

cytochrome P450 induction

cytochrome P450 Ki

UGT1A1 inhibition

metabolite profiling and identification

In vitro permeability

P - glycoprotein inhibition

Bioanalysis

bioanalytical method development and validation

Physicochemical properties

pKa and log P determination

Protein binding

brain tissue binding

blood to plasma ratio

cloe predict

Other

discovery bus

Physiological Modelling

cloe PK

cloe predict HIA

toxicology services

Publications

Challenges in the Prediction and Modelling of Oral Absorption and Bioavailability - 2010

Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals - 2009

Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery - 2008

Clinical relevance of predictive physiologically based pharmacokinetic methods - 2008

Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models - 2006

Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma - 2006

Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma - 2006

Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance - 2006

Automated QSPR through competitive workflow - 2005

Cloe® PK White Paper - 2004

Virtual humans for pharmacokinetics - 2004

Outsourcing discovery ADME screening - 2003

Posters

SOT 2009 Conference Poster: Development of more bioavaliable orally absorbed chemopreventive agents fron leads derived fron natural sources: Potential challenges

AAPS Drugs Transporters in ADME Workshop 2009: In vitro evaluation of P-glycoprotein inhibition using Loperamide as a probe substrate

DDT 2007 Conference poster: Combination of in vitro Caco-2 and aqueous solubility screens with in silico physiological modelling for the prediction of human intestinal absorption in early drug discovery

SBS 2007 Conference poster: Cloe® Screen MDR1-MDCK: A predictive model of human intestinal absorption and blood brain barrier permeability

SBS 2007 Conference poster: Development of a high throughput assay for the screening of mechanism-based CYP450 inhibition

NC3Rs Poster event 2007 - Computer models for replacing animal kinetic studies

9th European ISSX 2006 meeting poster - Development of high-throughput assays for the screening of reversible and mechanism - based cytocrome P450 inhibition by test compounds

9th European ISSX 2006 Meeting poster - Development of high-throughput PAMPA as an in vitro model of passive transcellular permeation

Presentation

Cyprotex 4th European Drug Discovery Workshop 2010: Transporters and cytochrome P450 interplay in defining hepatic drug clearance by Professor Brian Houston (Director of the Centre for Applied Pharmacokinetic Research, University of Manchester)

Cyprotex 4th European Drug Discovery Workshop 2010: Variations in permeability assays and their potential issues by Dr. Kevin Weigl (Senior Scientist, Abbott Products GmbH)

Cyprotex 4th European Drug Discovery Workshop 2010: Insoluble substances in in-vitro assays by Dr. Christa Kneip (Senior Scientist, Grünenthal)

Cyprotex 4th European Drug Discovery Workshop 2010: Special considerations of compound in vitro profiling during fast progression to clinical phases by Dr. Constance Höfer (Founder and Chief Scientist, DMPKORE)

Cyprotex 4th European Drug Discovery Workshop 2010: Physiologically based pharmacokinetic/ pharmacodynamic modelling for lead optimisation of CNS-Active therapeutics by Dr. Simon Thomas (Head of Scientific Computing, Cyprotex Discovery)

Cyprotex 5th NA Drug Discovery Workshop 2010: The role of hepatic and renal uptake transporters in drug discovery and development by Dr. Sonia de Morais (Director of DMPK, Abbott Labs)

Cyprotex 5th NA Drug Discovery Workshop 2010: Targeted solutions to DMPK problems: avoiding unnecessary screening by Dr. Bernard Murray (Senior Research Scientist I, Gilead)

Cyprotex 5th NA Drug Discovery Workshop 2010: Metabolite identification in drug discovery by Dr. Ron Aoyama (Senior Scientist I-DMPK, Exelixis)

Cyprotex 5th NA Drug Discovery Workshop 2010: PBPK modelling for the intergration of ADME data during drug discovery

Cyprotex 5th NA Drug Discovery Workshop 2010: Research strategies in LG and LO: combining in vitro and in vivo ADME approaches by Dr. Norman Huebert (Team Leader & Research Fellow ADME, Johnson & Johnson)

Cyprotex 5th NA Drug Discovery Workshop 2010: Drug metabolism in gut microbiota: a case study involving a pyridine N-oxide compound by Dr. Shichang Miao & Tim Stratton (Director DMPK, ChemoCentryx & Scientist, ChemoCentryx

Cyprotex 5th NA Drug Discovery Workshop 2010: Comparison of strategies for assessing metabolic stability in vitro

Cyprotex 5th NA Drug Discovery Workshop 2010: P-gp based drug interactions at the blood-brain barrier: Fact or fantasy? by Peng Hsiao (Research Assistant, University of Washington)

Cyprotex 4th NA Drug Discovery Workshop 2009: Physiologically Based Pharmacokinetics Modelling

Cyprotex 4th NA Drug Discovery Workshop 2009: Identification of reactive metabolites in early drug discovery

LRIG New Jersey 2008 presentation: Improving candidate quality through the prediction of clinical outcome

Cyprotex drug discovery workshop 2007 presentation: Identification of reactive metabolites in early drug discovery

Cyprotex drug discovery workshop 2007 presentation: Screening for P-gp inhibition in vitro: Assays and implications

Request a quotation or
one of our publications.

Quotation			Catalogue
ADME guide

Download a
PDF of our full
Product Catalogue.

This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.